I would encourage everyone to go into this with a positive attitude. It’s a disease state that hasn’t seen any new treatments or innovation since the 90’s. All the research articles online highlight the big potential for PCAB treatment and benefit. I don’t think training is bad at all. It’s mostly self study with minimal zoom calls. I don’t think the training manager is as bad as the gent / lady said. They have been very helpful and very very responsive and open to feedback. Think of it this way: there isn’t one perfect company out there. We all can poke holes in every company that exists and find things to criticize. So far, I’d fairly say that training exceeded my personal expectations. People have been so nice, friendly and supportive. Our manager is the sweetest, and quite frankly one of the nicest managers I’ve been exposed to in my 21 years career. Give this a fair chance and don’t judge it until you’re in the field to see the HCPs’ response and have a real field experience with your manager. This way your criticism would be objective rather than subjective. And for those who asked, yes the max limit of salaries aren’t high, and several may have taken a pay cut to come to Phathom (me included), but I have never seen a benefit package better than this. Unlimited vacation. $1500 per year for health and fitness expenses. Low monthly premiums for healthcare. Winter shutdown. ESP. And the list goes on. There are a lot worse packages out there and a lot worse companies. We haven’t had experience with Phathom to objectively say if they’re good or not. The fact that they have a way to put the medicine in patients’ hands if PAs are denied says a lot (trust me, I’ve worked with a company that had a very similar program to blink, and worked with one that didn’t and once the PA was denied that was it). Just be positive, but if you find a better opportunity take it because you have to do what you feel is best for yourself and your family. But I can almost guarantee that you’ll poke holes in the next company you’ll go to as well. Because we all can. I read people complain about the stock price. Well, don’t invest in the market at all because that’s what you’ll get with any stock for any new company. It’s a good time to buy, I believe. The approval came three weeks ahead of schedule. That’s positive. So far there are more positive signs than negative ones. We’ve seen worse. I’ve seen much worse. For a startup company I believe this is not as bad as some are making it out to be. Until we are in the field selling to HCPs, none of us can have an objective opinion on Phathom or the drug itself. So far, it’s at minimum net my personal expectations. I hope this helps, especially for the folks joining the wave 2 in December.